-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
JTX-1811 is a monoclonal antibody designed to selectively remove immunosuppressive tumor-immersive regulatory T (TITR) cells.
target of JTX-1811 is CCR8, a chemical factor subject that is rich in TITR cells.
when JTX-1811 binds to CCR8, it can target the removal of TITR cells through enhanced antibody-dependent cytotoxic mechanisms.
antibody will submit an IND application in the first half of 2021.
Jounce will be responsible for the early development of the JTX-1811 until IND approval is obtained, after which Gilead will have an exclusive interest in the development of the JTX-1811.
resources: s1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Retrieved 2020-09-01, from.